Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)  

作　　者：Fei Li Shou-Ching Tang 

机构地区：[1]The Editorial Office of Genes&Diseases,Chongqing,400046,China [2]Georgia Cancer Center,Medical College of Georgia,Augusta University,GA,USA

出　　处：《Genes & Diseases》2017年第1期1-3,共3页基因与疾病（英文）

摘　　要：We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate,ANG1005,in treating brain metastatic breast cancer.These results were presented by Dr.Tang at the recent annual meeting of the European Society for Medical Oncology(ESMO 2016 Congress).This development heralds an important step forward towards the development of effective chemotherapeutic agents,which can cross the bloodbrain-barrier and effectively treat and prevent the brain metastatic cancers.

关 键 词：ANG1005 Brain metastasis Breast cancer LRP-1 The blood-brain-barrier 

分 类 号：R73[医药卫生—肿瘤]